Northern Trust Corp Sells 53,079 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Northern Trust Corp reduced its stake in Regeneron Pharmaceuticals by 5.0%, owning 1,001,750 shares valued at approximately $635 million as of the latest SEC filing.
• Regeneron Pharmaceuticals reported a strong quarter with earnings per share of $12.89, significantly exceeding analysts' expectations of $8.43.
• The company recently announced a quarterly dividend of $0.88 per share, translating to an annual yield of 0.6% for investors.

Northern Trust Corp lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,001,750 shares of the biopharmaceutical company's stock after selling 53,079 shares during the quarter. Northern Trust Corp owned 0.92% of Regeneron Pharmaceuticals worth $635,340,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of REGN. Vanguard Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after buying an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the period. Goldman Sachs Group Inc. raised its stake in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after acquiring an additional 174,056 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after acquiring an additional 226,952 shares during the period. Finally, GAMMA Investing LLC raised its stake in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research analyst reports. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research report on Friday, August 1st. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Finally, BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Trading Down 1.5%

Shares of REGN stock traded down $8.68 during mid-day trading on Friday, reaching $589.48. 1,438,624 shares of the stock traded hands, compared to its average volume of 1,111,801. The stock's fifty day simple moving average is $549.27 and its two-hundred day simple moving average is $592.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.97 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the firm posted $11.56 earnings per share. The business's revenue for the quarter was up 3.6% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.